Invivyd’s (IVVD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.89 on Tuesday. The firm’s 50-day moving average is $0.99 and its two-hundred day moving average is $1.40. Invivyd has a 12-month low of $0.81 and a 12-month high of $5.20. The company has a market capitalization of $106.60 million, a PE ratio of -0.49 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The business had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.91 million. On average, analysts forecast that Invivyd will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Duquesne Family Office LLC purchased a new stake in shares of Invivyd during the second quarter worth about $629,000. Vanguard Group Inc. raised its holdings in Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after acquiring an additional 97,496 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the period. Tidal Investments LLC acquired a new stake in shares of Invivyd during the first quarter worth $126,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.